HC Wainwright reaffirmed their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a report published on Tuesday morning, TipRanks reports. They currently have a $15.00 target price on the stock.
AQST has been the topic of a number of other reports. Royal Bank of Canada reaffirmed a buy rating and issued a $8.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, March 25th. Wedbush reiterated a buy rating and set a $31.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research downgraded Aquestive Therapeutics from a buy rating to a hold rating in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aquestive Therapeutics presently has a consensus rating of Buy and a consensus price target of $14.67.
Shares of NASDAQ:AQST opened at $4.86 on Tuesday. The business’s 50 day moving average price is $5.35 and its 200-day moving average price is $4.36. The firm has a market capitalization of $168.92 million, a PE ratio of -1.92 and a beta of 3.61. Aquestive Therapeutics has a 1 year low of $1.41 and a 1 year high of $10.00.
In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 40,000 shares of Aquestive Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $4.50, for a total value of $180,000.00. Following the sale, the insider now owns 1,022,113 shares in the company, valued at $4,599,508.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Keith J. Kendall sold 50,000 shares of Aquestive Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $5.11, for a total value of $255,500.00. Following the completion of the sale, the chief executive officer now owns 638,964 shares in the company, valued at approximately $3,265,106.04. The disclosure for this sale can be found here. In the last quarter, insiders have sold 170,000 shares of company stock worth $743,500. 42.58% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of AQST. Spark Investment Management LLC purchased a new stake in Aquestive Therapeutics in the fourth quarter valued at $275,000. Credit Suisse AG purchased a new stake in Aquestive Therapeutics in the fourth quarter valued at $167,000. Trexquant Investment LP purchased a new stake in Aquestive Therapeutics in the fourth quarter valued at $130,000. Renaissance Technologies LLC purchased a new stake in Aquestive Therapeutics in the fourth quarter valued at $460,000. Finally, Oxford Asset Management LLP raised its position in Aquestive Therapeutics by 330.9% in the fourth quarter. Oxford Asset Management LLP now owns 311,539 shares of the company’s stock valued at $1,813,000 after purchasing an additional 239,243 shares during the period. Institutional investors own 52.68% of the company’s stock.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.
Further Reading: Earnings Per Share (EPS)
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.